Metrika

  • citati u SCIndeksu: [1]
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:2
  • preuzimanja u poslednjih 30 dana:1

Sadržaj

članak: 8 od 10  
Back povratak na rezultate
2017, vol. 74, br. 4, str. 317-322
Uticaj steatoze jetre na uspeh antivirusne terapije hroničnog hepatitisa C
aKlinički centar Vojvodine, Klinika za infektivne bolesti, Novi Sad + Univerzitet u Novom Sadu, Medicinski fakultet
bKlinički centar Vojvodine, Klinika za infektivne bolesti, Novi Sad
Sažetak
Uvod/Cilj. Hronični hepatitis C i steatoza jetre se često javljaju udruženo kod iste osobe, a steatoza jetre može dovesti do pogoršanja bolesti jetre i može smanjiti uspeh lečenja hroničnog hepatitisa C. Lečenjem jedne bolesti povoljno se utič e na ishod lečenja druge bolesti. Cilj ovog rada bio je da se utvrdi učestalost steatoze jetre kod bolesnika sa hroničnim hepatitisom C i da se ispita uticaj steatoze jetre i drugih prediktora na uspeh antivirusne terapije hroničnog hepatitisa C. Metode. U studiju su bila uključena 123 bolesnika sa hroničnim hepatitisom C, koji su lečeni pegilovanim interferonom alfa 2a u kombinaciji sa ribavirinom. Bolesnici su na osnovu prisustva steatoze jetre podeljeni u dve grupe, grupu I sa 43 bolesnika i steatozom jetre i grupu II sa 80 bolesnika bez steatoze jetre. Uspeh lečenja ocenili smo na osnovu postignutog stabilnog virusološkog odgovora. Rezultati. Postojanje steatoze utvrđeno je kod 34,96% bolesnika. Ukupan uspeh antivirusne terapije postignut je kod 74,79% bolesnika. Uspeh antivirusne terapije zabeležen je kod 62,79% bolesnika sa steatozom jetre i kod 81,25% bolesnika bez steatoze (p < 0,05). Uspeh antivirusnog lečenja postignut je kod 80,95% bolesnika sa steatozom jetre i genotipom 3 virusa hepatitisa C. Prediktori uspešnosti antivirusne terapije hroni čnog hepatitisa C u našem radu bili su starost bolesnika, dužina trajanja infekcije, genotip 3, steatoza i izražena fibroza jetre. Zaključak. Steatoza jetre često je prisutna kod bolesnika sa hroničnim hepatitisom C i ima negativan uticaj na efikasnost antivirusne terapije kod bolesnika sa infekcijom genotipom non-3 hepatitis C virusa. Zbog toga se steatoza jetre kod ovih bolesnika mora eliminisati ili lečiti pre primene antivirusne terapije.
Reference
Abdel-Aziz, M., Abdel-Aziz, A., El-Arman, M. (2009) Non alcoholic fatty liver diseases in chronic Hepatitis C: Impact on end treatment virologic response. IJCRIMPH, 1(9): 215-31
Abenavoli, L. (2014) Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. World Journal of Gastroenterology, 20(41): 15233
Ansaldi, F., Orsi, A., Sticchi, L., Bruzzone, B., Icardi, G. (2014) Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World Journal of Gastroenterology, 20(29): 9633-52
Arrese, M., Riquelme, A., Soza, A., Barrera, F.M., Soza, A. (2010) Insulin resistance, hepatic steatosis and hepatitis C: A complex relationship with relevant clinical implications. Ann Hepatol, 9(Suppl 1): 112-8
Asselah, T., Estrabaud, E., Bieche, I., Lapalus, M., De, M.S., Vidaud, M., Saadoun, D., Soumelis, V., Marcellin, P. (2010) Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver International, 30(9): 1259-1269
Blachier, M., Leleu, H., Peck-Radosavljevic, M., Valla, D., Roudot-Thoraval, F. (2013) The burden of liver disease in Europe: A review of available epidemiological data. Journal of Hepatology, 58(3): 593-608
Castera, L., Chouteau, P., Hezode, C., Zafrani, E., Dhumeaux, D., Pawlotsky, J. (2005) Hepatitis C Virus-Induced Hepatocellular Steatosis. American Journal of Gastroenterology, 100(3): 711-715
Cornberg, M., Razavi, H.A., Alberti, A., Bernasconi, E., Buti, M., Cooper, C., Dalgard, O., Dillion, J.F., Flisiak, R., Forns, X., Frankova, S., Goldis, A., Goulis, I., Halota, W., Hunyady, B., Laggin (2011) A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver International, 31: 30-60
Cross, T.J.S., Quaglia, A., Nolan, J., Hughes, S., Harrison, P.M. (2010) Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection?. Journal of Medical Virology, 82(6): 958-964
Cross, T.J. S., Rashid, M.M., Berry, P.A., Harrison, P.M. (2010) The importance of steatosis in chronic hepatitis C infection and its management: A review. Hepatology Research, 40(3): 237-247
Deborah, F.N., Green, J.H., Weber, H.M., Stephen, S., Lane, S.E., Ting, A.Y., Watson, J.P. (2014) Hepatitis C Virus Treatment in the 'Real-World’: How Well Do 'Real’ Patients Respond?. Journal of Clinical and Experimental Hepatology, 4(3): 214-220
EASL Clinical Practice Guidelines (2011) EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. Journal of Hepatology, 55(2): 245-264
Ferguson, M.C. (2011) Current Therapies for Chronic Hepatitis C. Pharmacotherapy, 31(1): 92-111
Fierbinţeanu-Braticevici, C., Mohora, M., Tribus, L., Petrişor, A., Creţoiu, S.M., Creţoiu, D., et al. (2010) Hepatocyte steatosis in patients infected with genotype 1 hepatitis C virus. Rom J Morphol Embryol, 51(2): 235-42
Hwang, S., Lee, S. (2011) Hepatic steatosis and hepatitis C: Still unhappy bedfellows?. Journal of Gastroenterology and Hepatology, 26: 96-101
Jovanović, M., Konstantinović, L., Kostić, V., Vrbić, M., Popović, L. (2009) Efficiency of a combined peginterferon alpha-2a and ribavarin therapy in intravenous opiate substances abusers with chronic hepatitis C. Vojnosanitetski pregled, vol. 66, br. 10, str. 791-795
Kleiner, D.E., Brunt, E.M., Van, N.M., Behling, C., Contos, M.J., Cummings, O.W., Ferrell, L.D., Liu, Y., Torbenson, M.S., Unalp-Arida, A., Yeh, M., McCullough, A.J., Sanyal, A.J. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 41(6): 1313-1321
Koike, K. (2009) Steatosis, liver injury, and hepatocarcinogenesis in hepatitis C viral infection. Journal of Gastroenterology, 44(S19): 82-88
Kuljić-Kapulica, N., Jovanović, D., Savić, D., Ristanović, E., Nožić, D., Rajić, R. (2010) Therapy of chronic hepatitis C: Virologic response monitoring. Vojnosanitetski pregled, vol. 67, br. 11, str. 923-927
Mchutchison, J.G., Lawitz, E.J., Shiffman, M.L., Muir, A.J., Galler, G.W., Mccone, J., et al. (2009) Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med, 361(6): 580-93
Mohd, H.K., Groeger, J., Flaxman, A.D., Wiersma, S.T. (2013) Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology, 57(4): 1333-1342
Negro, F., Clément, S. (2009) Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C. Journal of Viral Hepatitis, 16(10): 681-688
Negro, F. (2010) Hepatitis C Virus-Induced Steatosis: An Overview. Digestive Diseases, 28(1): 294-299
Negro, F. (2014) Facts and fictions of HCV and comorbidities: Steatosis, diabetes mellitus, and cardiovascular diseases. Journal of Hepatology, 61(1): S69-S78
Persico, M. (2010) Steatosis as a co-factor in chronic liver diseases. World Journal of Gastroenterology, 16(10): 1171
Rodriguez-Torres, M., Govindarajan, S., Diago, M., Morgan, T., Anand, B., Barange, K., Suter, F., Lin, A., Hooper, G., Shiffman, M. (2009) Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon α-2a (40KD) (PEGASYS ® ) plus ribavirin (COPEGUS. Liver International, 29(2): 237-241
Rubbia-Brandt, L., Quadri, R., Abid, K., Giostra, E., Malé, P., Mentha, G., Spahr, L., Zarski, J., Borisch, B., Hadengue, A., Negro, F. (2000) Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. Journal of Hepatology, 33(1): 106-115
Sanyal, A.J. (2011) Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C. Liver International, 31: 23-28
Savvoula, S., Dimitrios, C., George, P., Spilios, M., Christos, T., John, G. (2012) The Impact of Host Metabolic Factors on Treatment Outcome in Chronic Hepatitis C. Gastroenterology Research and Practice, 2012: 1-9
Soresi, M., Tripi, S., Franco, V., Giannitrapani, L., Alessandri, A., Rappa, F., Vuturo, O., Montalto, G. (2006) Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. Liver International, 26(9): 1119-1125
Svirtlih, N. (2007) Hepatitis C virus genotypes in Serbia and Montenegro: The prevalence and clinical significance. World Journal of Gastroenterology, 13(3): 355
Szanto, P., Grigorescu, M., Dumitru, I., Serban, A. (2006) Steatosis in hepatitis C virus infection: Response to anti-viral therapy. J Gastrointestin Liver Dis, 15(2): 117-24
Thomopoulos, K.C., Theocharis, G.J., Tsamantas, A.C., Siagris, D., Dimitropoulou, D., Gogos, C.A., Labropoulou-Karatza, C. (2005) Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C. European journal of gastroenterology & hepatology, 17(2): 149-53
Werling, K., Schaff, Z., Dinya, E., Tulassay, Z. (2010) Effect of Liver Steatosis on Therapeutic Response in Chronic Hepatitis C Virus Genotype 1 Infected Patients in Hungary. Pathology & Oncology Research, 16(2): 149-157
Westin, J., Lagging, M., Dhillon, A. P., Norkrans, G., Romero, A. I., Pawlotsky, J.-M., Zeuzem, S., Schalm, S. W., Verheij-Hart, E., Negro, F., Missale, G., Neumann, A. U., Hellstrand, K. (2007) Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. Journal of Viral Hepatitis, 14(1): 29-35
Younossi, Z.M., McCullough, A.J. (2009) Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver International, 29: 3-12
Zhu, Y. (2013) Antiviral treatment of hepatitis C virus infection and factors affecting efficacy. World Journal of Gastroenterology, 19(47): 8963
 

O članku

jezik rada: engleski
vrsta rada: izvorni naučni članak
DOI: 10.2298/VSP150826190P
objavljen u SCIndeksu: 08.04.2017.
metod recenzije: dvostruko anoniman
Creative Commons License 4.0